36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
3 citations
,
October 2021 in “Brain Sciences” Long-term use of Risperidone may be linked to a serious skin condition in bipolar patients, affecting their overall well-being.
69 citations
,
October 2013 in “Journal of Clinical Psychopharmacology” Naltrexone did not significantly reduce hair pulling but improved cognitive flexibility.
Certain medications, especially nervous system drugs, can cause insomnia, with risks varying by age and gender.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
October 2023 in “Journal of the American Academy of Dermatology” Clascoterone cream could be used for other skin conditions affected by hormones.
Baricitinib helps regrow hair in teens with severe alopecia areata.
October 2025 in “Reactions Weekly” September 2025 in “Reactions Weekly”
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
June 2019 in “Reactions Weekly”
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
July 2025 in “Journal of Investigative Dermatology” Breezula® may be more effective than Minoxidil in promoting hair growth by reducing a hair growth inhibitor.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
January 2025 in “Journal of Prescribing Practice” July 2006 in “Inpharma Weekly” 1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia”
1 citations
,
June 2017 in “Skin” Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
February 2006 in “Inpharma Weekly” February 2025 in “Iranian journal of pharmaceutical research”
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
8 citations
,
September 1993 in “Human psychopharmacology” Some antidepressants can cause rare hair loss, which can significantly affect patients' well-being.
January 2021 in “Journal of clinical & experimental dermatology research” LustrivaTM improves hair thickness and reduces facial wrinkles safely.